1. Bade BC and Dela Cruz CS: Lung cancer 2020: Epidemiology,
etiology, and prevention. Clin Chest Med 41: 1‑24, 2020.
2. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP
and Vansteenkiste J; International Adjuvant Lung Cancer Trial
Collaborative Group: Cisplatin‑based adjuvant chemotherapy
in patients with completely resected non‑small‑cell lung cancer.
N Engl J Med 350: 351‑360, 2004.
3. Douillard JY, Tribodet H, Aubert D, Shepherd FA, Rosell R,
Ding K, Veillard AS, Seymour L, Le Chevalier T, Spiro S, et al:
Adjuvant cisplatin and vinorelbine for completely resected
non‑small cell lung cancer: Subgroup analysis of the lung adju‑
vant cisplatin evaluation. J Thorac Oncol 5: 220‑228, 2010.
4. Asamura H, Goya T, Koshiishi Y, Sohara Y, Eguchi K, Mori M,
Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, et al: A
Japanese lung cancer registry study: Prognosis of 13,010 resected
lung cancers. J Thorac Oncol 3: 46‑52, 2008.
5. Nadkar A, Pungaliya C, Drake K, Zajac E, Singhal SS and
Awasthi S: Therapeutic resistance in lung cancer. Expert Opin
Drug Metab Toxicol 2: 753‑777, 2006.
6. Gottesman MM: Mechanisms of cancer drug resistance. Annu
Rev Med 53: 615‑627, 2002.
7. Gottesman MM and Ling V: The molecular basis of multidrug
resistance in cancer: The early years of P‑glycoprotein research.
FEBS Lett 580: 998‑1009, 2006.
8. Sadeghi MR, Jeddi F, Soozangar N, Somi MH, Shirmohamadi M,
Khaze V and Samadi N: Nrf2/P‑glycoprotein axis is associated
with clinicopathological characteristics in colorectal cancer.
Biomed Pharmacother 104: 458‑464, 2018.
9. Nakanishi T, Menju T, Nishikawa S, Takahashi K, Miyata R,
Shikuma K, Sowa T, Imamura N, Hamaji M, Motoyama H, et al:
The synergistic role of ATP‑dependent drug efflux pump and
focal adhesion signaling pathways in vinorelbine resistance in
lung cancer. Cancer Med 7: 408‑419, 2018.
10. Zhang S, Qi Q, Chan CB, Zhou W, Chen J, Luo HR, Appin C,
Brat DJ and Ye K: Fyn‑phosphorylated PIKE‑A binds and
inhibits AMPK signaling, blocking its tumor suppressive activity.
Cell Death Differ 23: 52‑63, 2016.
11. Singh MM, Howard A, Irwin ME, Gao Y, Lu X, Multani A and
Chandra J: Expression and activity of Fyn mediate proliferation
and blastic features of chronic myelogenous leukemia. PLOS
One 7: e51611, 2012.
12. Posadas EM, Al‑Ahmadie H, Robinson VL, Jagadeeswaran R,
Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta KJ,
Stadler WM, et al: FYN is overexpressed in human prostate
cancer. BJU Int 103: 171‑177, 2009.
13. Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW,
Lykkesfeldt AE and Ditzel HJ: Gene expression profiling identi‑
fies FYN as an important molecule in tamoxifen resistance and
a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene 34: 1919‑1927, 2015.
14. Chiu WH, Luo SJ, Chen CL, Cheng JH, Hsieh CY, Wang CY,
Huang WC, Su WC and Lin CF: Vinca alkaloids cause aberrant
ROS‑mediated JNK activation, Mcl‑1 downregulation, DNA
damage, mitochondrial dysfunction, and apoptosis in lung
adenocarcinoma cells. Biochem Pharmacol 83: 1159‑1171, 2012.
12
TAMARI et al: Nrf2/p-Fyn/ABCB1 AXIS IN VINORELBINE RESISTANCE IN LUNG CANCER
15. Xue D, Zhou X and Qiu J: Emerging role of NRF2 in ROS‑mediated
tumor chemoresistance. Biomed Pharmacother 131: 110676,
2020.
16. Ren D, Villeneuve NF, Jiang T, Wu T, Lau A, Toppin HA and
Zhang DD: Brusatol enhances the efficacy of chemotherapy by
inhibiting the Nrf2‑mediated defense mechanism. Proc Natl
Acad Sci USA 108: 1433‑1438, 2011.
17. Yoshino H, Murakami K, Nawamaki M and Kashiwakura I:
Effects of Nrf2 knockdown on the properties of irradiated
cell conditioned medium from A549 human lung cancer cells.
Biomed Rep 8: 461‑465, 2018.
18. Shin BY, Jin SH, Cho IJ and Ki SH: Nrf2‑ARE pathway regu‑
lates induction of Sestrin‑2 expression. Free Radic Biol Med 53:
834‑841, 2012.
19. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD: Dual
roles of Nrf2 in cancer. Pharmacol Res 58: 262‑270, 2008.
20. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, Hoque MO,
Herman JG, Baylin SB, Sidransky D, Gabrielson E, et al:
Dysfunctional KEAP1‑NRF2 interaction in non‑small‑cell lung
cancer. PLoS Med 3: e420, 2006.
21. Feng SL, Luo HB, Cai L, Zhang J, Wang D, Chen YJ, Zhan HX,
Jiang ZH and Xie Y: Ginsenoside Rg5 overcomes chemothera‑
peutic multidrug resistance mediated by ABCB1 transporter:
In vitro and in vivo study. J Ginseng Res 44: 247‑257, 2020.
22. Goldstraw P: New TNM classification: Achievements and
hurdles. Transl Lung Cancer Res 2: 264‑272, 2013.
23. Huang Z, Ouyang M, Lu S, Wang Y and Peng Q: Optogenetic
control for investigating subcellular localization of Fyn kinase
activity in single live cells. J Mol Biol 432: 1901‑1909, 2020.
24. Resh MD: Fyn, a Src family tyrosine kinase. Int J Biochem Cell
Biol 30: 1159‑1162, 1998.
25. Kitamura H and Motohashi H: NRF2 addiction in cancer cells.
Cancer Sci 109: 900‑911, 2018.
26. Singh A, Boldin‑Adamsky S, Thimmulappa RK, Rath SK,
Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F,
Watson WH, et al: RNAi‑mediated silencing of nuclear factor
erythroid‑2‑related factor 2 gene expression in non‑small cell
lung cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res 68: 7975‑7984, 2008.
27. Bryan HK, Olayanju A, Goldring CE and Park BK: The Nrf2 cell
defence pathway: Keap1‑dependent and ‑independent mecha‑
nisms of regulation. Biochem Pharmacol 85: 705‑717, 2013.
28. Osburn WO and Kensler TW: Nrf2 signaling: An adaptive
response pathway for protection against environmental toxic
insults. Mutat Res 659: 31‑39, 2008.
29. Jaiswal AK: Nrf2 signaling in coordinated activation of antioxi‑
dant gene expression. Free Radic Biol Med 36: 1199‑1207, 2004.
30. Hayashi A, Suzuki H, Itoh K, Yamamoto M and Sugiyama Y:
Transcription factor Nrf2 is required for the constitutive
and inducible expression of multidrug resistance‑associated
protein 1 in mouse embryo fibroblasts. Biochem Biophys Res
Commun 310: 824‑829, 2003.
31. Vollrath V, Wielandt AM, Iruretagoyena M and Chianale J: Role
of Nrf2 in the regulation of the MRP2 (ABCC2) gene. Biochem
J 395: 599‑609, 2006.
32. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y,
Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, et al:
Nrf2 enhances cell proliferation and resistance to anticancer
drugs in human lung cancer. Clin Cancer Res 15: 3423‑3432,
2009.
33. Tarumoto T, Nagai T, Ohmine K, Miyoshi T, Nakamura M,
Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N and
Ozawa K: Ascorbic acid restores sensitivity to imatinib
via suppression of Nrf2‑dependent gene expression in the
imatinib‑resistant cell line. Exp Hematol 32: 375‑381, 2004.
34. Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin A, Li X, Wu J and
Tang X: Oxaliplatin activates the Keap1/Nrf2 antioxidant system
conferring protection against the cytotoxicity of anticancer
drugs. Free Radic Biol Med 70: 68‑77, 2014.
35. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG
and Kang KW: Increased expression of Nrf2/ARE‑dependent
anti‑oxidant proteins in tamoxifen‑resistant breast cancer cells.
Free Radic Biol Med 45: 537‑546, 2008.
36. Hu Q, Qin Y, Xiang J, Liu W, Xu W, Sun Q, Ji S, Liu J, Zhang Z,
Ni Q, et al: dCK negatively regulates the NRF2/Are axis and
ROS production in pancreatic cancer. Cell Prolif 51: e12456,
2018.
37. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, Yamamoto M
and Hirohashi S: Genetic alteration of Keap1 confers constitutive
Nrf2 activation and resistance to chemotherapy in gallbladder
cancer. Gastroenterology 135: 1358‑1368, 1368.e1351‑e1354, 2008.
38. Arias‑Salgado EG, Lizano S, Sarkar S, Brugge JS, Ginsberg MH
and Shattil SJ: Src kinase activation by direct interaction with the
integrin beta cytoplasmic domain. Proc Natl Acad Sci USA 100:
13298‑13302, 2003.
39. Reddy KB, Smith DM and Plow EF: Analysis of Fyn function in
hemostasis and alphaIIbbeta3‑integrin signaling. J Cell Sci 121:
1641‑1648, 2008.
40. Cooper J and Giancotti FG: Integrin signaling in cancer:
Mechanotransduction, stemness, epithelial plasticity, and thera‑
peutic resistance. Cancer Cell 35: 347‑367, 2019.
41. Campbell EJ, McDuff E, Tatarov O, Tovey S, Brunton V,
Cooke TG and Edwards J: Phosphorylated c‑Src in the nucleus is
associated with improved patient outcome in ER‑positive breast
cancer. Br J Cancer 99: 1769‑1774, 2008.
42. Kaplan KB, Swedlow JR, Varmus HE and Morgan DO:
Association of p60c‑src with endosomal membranes in mamma‑
lian fibroblasts. J Cell Biol 118: 321‑333, 1992.
43. Sandilands E, Cans C, Fincham VJ, Brunton VG, Mellor H,
Prendergast GC, Norman JC, Superti‑Furga G and Frame MC:
RhoB and actin polymerization coordinate Src activation with
endosome‑mediated delivery to the membrane. Dev Cell 7:
855‑869, 2004.
44. Nishikawa S, Menju T, Takahashi K, Miyata R, Sonobe M,
Yoshizawa A and Date H: Prognostic significance of phos‑
phorylated Fyn in patients with lung adenocarcinoma after lung
resection. Ann Thorac Cardiovasc Surg 25: 246‑252, 2019.
45. Wakabayashi N, Itoh K, Wakabayashi J, Motohashi H, Noda S,
Takahashi S, Imakado S, Kotsuji T, Otsuka F, Roop DR, et al:
Keap1‑null mutation leads to postnatal lethality due to constitu‑
tive Nrf2 activation. Nat Genet 35: 238‑245, 2003.
46. Kang MI, Kobayashi A, Wakabayashi N, Kim SG and
Yamamoto M: Scaffolding of Keap1 to the actin cytoskeleton
controls the function of Nrf2 as key regulator of cytoprotective
phase 2 genes. Proc Natl Acad Sci USA 101: 2046‑2051, 2004.
47. Kaspar JW and Jaiswal AK: Tyrosine phosphorylation controls
nuclear export of Fyn, allowing Nrf2 activation of cytoprotective
gene expression. FASEB J 25: 1076‑1087, 2011.
48. Jain AK and Jaiswal AK: GSK‑3beta acts upstream of Fyn kinase
in regulation of nuclear export and degradation of NF‑E2 related
factor 2. J Biol Chem 282: 16502‑16510, 2007.
49. Tokunaga Y, Hosogi H, Hoppou T, Nakagami M, Tokuka A and
Ohsumi K: Effects of MDR1/P‑glycoprotein expression on prog‑
nosis in advanced colorectal cancer after surgery. Oncol Rep 8:
815‑819, 2001.
50. Li W and Song M: Expression of multidrug resistance proteins in
invasive ductal carcinoma of the breast. Oncol Lett 8: 2103‑2109,
2014.
51. Park SH, Park CJ, Kim DY, Lee BR, Kim YJ, Cho YU and Jang S:
MRP1 and P‑glycoprotein expression assays would be useful in
the additional detection of treatment non‑responders in CML
patients without ABL1 mutation. Leuk Res 39: 1109‑1116, 2015.
52. Kawasaki Y, Ishigami S, Arigami T, Uenosono Y, Yanagita S,
Uchikado Y, Kita Y, Nishizono Y, Okumura H, Nakajo A, et al:
Cl i n icopat holog ica l sig n i f ica nc e of nuclea r fa ctor
(erythroid‑2)‑related factor 2 (Nrf2) expression in gastric cancer.
BMC Cancer 15: 5, 2015.
53. Zhang J, Jiao Q, Kong L, Yu J, Fang A, Li M and Yu J: Nrf2
and Keap1 abnormalities in esophageal squamous cell carcinoma
and association with the effect of chemoradiotherapy. Thorac
Cancer 9: 726‑735, 2018.
54. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC,
Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN, et al:
Nrf2 and Keap1 abnormalities in non‑small cell lung carcinoma
and association with clinicopathologic features. Clin Cancer
Res 16: 3743-3753, 2010.
...
論文の公開元へ
